Crossmark

Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Crossref DOI link: https://doi.org/10.1186/s40360-018-0203-8

Published Online: 2018-03-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eaton, Natalie http://orcid.org/0000-0002-0815-3162
Cabanas, Hélène

Balinas, Cassandra

Klein, Anne

Staines, Donald

Marshall-Gradisnik, Sonya
Funding

Funding for this research was provided by:

Stafford Fox Medical Research Foundation (48978)

Mr Douglas Stutt (4578)

Change for ME (4575)

Blake Beckett Foundation (4579)

Alison Hunter Memorial Foundation (4570)
License Information

Text and Data Mining valid from 2018-03-27
More Information

Article History

Received: 8 August 2017

Accepted: 16 March 2018

First Online: 27 March 2018

Competing interest

: The authors declare that they have no competing interest.

: This study was approved by the Griffith University Human Research Ethics Committee (HREC/15/QGC/63). Written consent was provided by each participant prior to blood collection.

: Not Applicable.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.